196. Nordihydroguaiaretic Acid (NDGA) Improves Function of Antigen-Specific T-Cells Stimulated by Capsid-Optimized AAV6 Vectors

Daniel Zhang,Chen Ling,George Aslanidi

DOI: https://doi.org/10.1016/s1525-0016(16)33005-2

IF: 12.91

2016-01-01

Molecular Therapy

Abstract:Cancer, a leading cause of death in the human population today, is generally treated with rigorous surgery followed by intensive chemotherapeutic methods, both of which have adverse toxic side effects. Immunotherapy represents an attractive alternative since it is based on activation of the host immune system. We recently showed that capsid-optimized AAV6-S663V+T492V vectors expressing a tumor-associated antigen are able to initiate specific peripheral T-cell response and suppress tumor progression as well as extend survival in a prostate cancer animal model (J Immunother., 38: 292-298, 2015). However, vaccination based on AAV6 vectors alone was not able to completely overcome the adverse effect of tumor microenvironment and tumor-induced immune dysfunction. Tumor-associated macrophages (TAMs) are prominent components of solid tumors. TAMs exhibit distinct phenotypes and function, and negatively contribute to immune system evasion. Previously published data indicate that inhibition of lipoxygenase (15-LOX2), a key enzyme contributing to TAM function, is critical to overcome tumor resistance and facilitate immunotherapy treatment. In our studies presented here, we first showed that 15-LOX2 is expressed in mouse prostate cancer cells, RM1, growing subcutaneously in C57BL/6 mice, but not in cells growing in culture. We also showed that LOX inhibitors, such as a plant-derived compound, nordihydroguaiaretic acid (NDGA), could restore the function of specific cytotoxic T-cells co-cultured with TAMs in a concentration-dependent manner. Splenocytes from C57BL/6 mice injected intra-muscularly with capsid-optimized AAV6 vectors expressing prostatic aid phosphatase (PAP) were isolated 14 days after vector injection. T-cells were incubated in the presence or absence of RM1 tumor cell extracts and NDGA for 2 hours and then used in killing assays against cultured RM1 cells. Two-color fluorescence assays of cell-mediated cytotoxicity was used to estimate the percentage of dead/alive target cells and a killing curve was generated with different effectors to target cell ratios. Our data indicated that the killing ability of T-cells initiated by capsid-optimized AAV6 vector injection and incubated with RM1 tumor-derived TAMs was approximately 3-fold lower than original activity T-cell. NDGA at a concentration of 10 uM had limited effect on the T-cell activity, but 25 µM NDGA restored the function of the T-cells to approximately 90% of the original activity. In our currently ongoing studies, we are using a combination of capsid-optimized AAV6 vector-mediated immune activation with the NDGA-treatment to corroborate whether a synergetic therapeutic effect can be achieved in an animal model. If successful, this approach could prove useful in the potential clinical application.